Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MAC stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/S.
Implied fair value · at MAC's multiple
Needs MAC P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MACERICH CO · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Illumina, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SIMON PROPERTY GROUP INC /DE/
MAC vs SPG
KIMCO REALTY CORP
MAC vs KIM
Brixmor Property Group Inc.
MAC vs BRX
REGENCY CENTERS CORP
MAC vs REG
FEDERAL REALTY INVESTMENT TRUST
MAC vs FRT
THERMO FISHER SCIENTIFIC INC.
MAC vs TMO
AGILENT TECHNOLOGIES, INC.
MAC vs A
DANAHER CORP /DE/
MAC vs DHR
BIO-RAD LABORATORIES, INC.
MAC vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
MAC vs PACB
Natera, Inc.
MAC vs NTRA
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MAC can sustain revenue growth while improving margins and reducing leverage, then a small overweight could be justified because ILMN-based valuation shows only 2.0% downside/upside and the stock remains within its historical range; otherwise, the weak quality and balance sheet metrics argue for caution.
MAC's current price of $25.46 is only modestly below the implied price of $25.97, suggesting about 2.0% upside on the P/S framework. The valuation picture is mixed because MAC trades at the same P/S as ILMN, but on earnings and asset-quality measures it looks materially weaker.
Supporting Metrics
